MultiOmic Health presents at LSX Investival 2024
Watch our CEO Robert Thong talk about how we are advancing precision medicine for metabolic-syndrome-related conditions at the LSX Investival Showcase in London.
MultiOmic Health announces discovery of novel endotypes and biomarkers for diabetic kidney disease
MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney disease (DKD) patients.
Leveraging deep omics data to tackle a global health challenge with precision
We are excited to announce our feature in the most recent edition of Nature Portfolio’s Biopharma Dealmakers discussing the advances in AI-driven drug development.